Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-2129 in Chinese Patients With Diabetic Peripheral Neuropathic Pain
NCT07377721Phase 1Recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-2129 in diabetic polyneuropathy (DPN) (4 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoint: Average Daily Pain Score at 4 weeks. Started Mar 2026; status: recruiting.
02
Drugs
HRS-2129
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT07377721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07377721.